Moreover, treatment with the anti-VEGF-A antibody bevacizumab strongly impaired Anaplastic Large Cell Lymphoma (containing EML4-ALK rearrangement) growth in mouse xenografts [41]. The gene discussed is VEGFA; the disease is anaplastic large cell lymphoma.